I believe the recent sell-off induced from the recent patient death with liver failure after receiving Elevidys (their DMD gene therapy) is an isolated case.
Unfortunately, these things are bound to happen in biotech and liver risks we’re already known with AAV-mediated gene therapies; however, more then 800 other patients have been treated using Elevidys giving it a favorable risk-profile.
Position:
2,826 Shares
Obligatory, Not Financial Advice.
